Cargando…
The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective
BACKGROUND: Benchmark data on the population-level economic burden are critical to inform policymakers about liver cancer control. However, comprehensive data in China are currently limited. METHODS: A prevalence-based approach from a societal perspective was used to quantify the annual economic bur...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308023/ https://www.ncbi.nlm.nih.gov/pubmed/35870941 http://dx.doi.org/10.1186/s12962-022-00370-3 |
_version_ | 1784752896605159424 |
---|---|
author | Cao, Meng-Di Liu, Cheng-Cheng Wang, Hong Lei, Lin Cao, Maomao Wang, Yuting Li, He Yan, Xin-Xin Li, Yan-Jie Wang, Xin Peng, Ji Qu, Chunfeng Feletto, Eleonora Shi, Ju-Fang Chen, Wanqing |
author_facet | Cao, Meng-Di Liu, Cheng-Cheng Wang, Hong Lei, Lin Cao, Maomao Wang, Yuting Li, He Yan, Xin-Xin Li, Yan-Jie Wang, Xin Peng, Ji Qu, Chunfeng Feletto, Eleonora Shi, Ju-Fang Chen, Wanqing |
author_sort | Cao, Meng-Di |
collection | PubMed |
description | BACKGROUND: Benchmark data on the population-level economic burden are critical to inform policymakers about liver cancer control. However, comprehensive data in China are currently limited. METHODS: A prevalence-based approach from a societal perspective was used to quantify the annual economic burden of liver cancer in China from 2019 to 2030. Detailed per-case data on medical/non-medical expenditure and work-loss days were extracted from a multicenter survey. The numbers/rates of new/prevalent cases and deaths, survival, and population-related parameters were extracted from the Global Burden of Disease 2019 and the literature. All expenditure data were reported in both 2019 Chinese Yuan (CNY) and United States dollar (US$, for main estimations). RESULT: The overall economic burden of liver cancer was estimated at CNY76.7/US$11.1 billion in China in 2019 (0.047% of the local GDP). The direct expenditure was CNY21.6/US$3.1 billion, including CNY19.7/US$2.9 billion for medical expenditure and CNY1.9/US$0.3 billion for non-medical expenditure. The indirect cost was CNY55.1/US$8.0 billion (71.8% of the overall burden), including CNY3.0/US$0.4 billion due to disability and CNY52.0/US$7.5 billion due to premature death. The total burden would increase to CNY84.2/US$12.2 billion, CNY141.7/US$20.5 billion, and CNY234.3/US$34.0 billion in 2020, 2025, and 2030, accounting for 0.102%, 0.138%, and 0.192% of China's GDP, respectively. However, if China achieves the goals of Healthy China 2030 or the United Nations' Sustainable Development Goals for non-communicable diseases, the burden in 2030 would be < CNY144.4/US$20.9 billion. CONCLUSIONS: The population-level economic burden of liver cancer in China is currently substantial and will consistently increase in the future. Sustainable efforts in primary and secondary interventions for liver cancer need to be further strengthened. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12962-022-00370-3. |
format | Online Article Text |
id | pubmed-9308023 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-93080232022-07-24 The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective Cao, Meng-Di Liu, Cheng-Cheng Wang, Hong Lei, Lin Cao, Maomao Wang, Yuting Li, He Yan, Xin-Xin Li, Yan-Jie Wang, Xin Peng, Ji Qu, Chunfeng Feletto, Eleonora Shi, Ju-Fang Chen, Wanqing Cost Eff Resour Alloc Research BACKGROUND: Benchmark data on the population-level economic burden are critical to inform policymakers about liver cancer control. However, comprehensive data in China are currently limited. METHODS: A prevalence-based approach from a societal perspective was used to quantify the annual economic burden of liver cancer in China from 2019 to 2030. Detailed per-case data on medical/non-medical expenditure and work-loss days were extracted from a multicenter survey. The numbers/rates of new/prevalent cases and deaths, survival, and population-related parameters were extracted from the Global Burden of Disease 2019 and the literature. All expenditure data were reported in both 2019 Chinese Yuan (CNY) and United States dollar (US$, for main estimations). RESULT: The overall economic burden of liver cancer was estimated at CNY76.7/US$11.1 billion in China in 2019 (0.047% of the local GDP). The direct expenditure was CNY21.6/US$3.1 billion, including CNY19.7/US$2.9 billion for medical expenditure and CNY1.9/US$0.3 billion for non-medical expenditure. The indirect cost was CNY55.1/US$8.0 billion (71.8% of the overall burden), including CNY3.0/US$0.4 billion due to disability and CNY52.0/US$7.5 billion due to premature death. The total burden would increase to CNY84.2/US$12.2 billion, CNY141.7/US$20.5 billion, and CNY234.3/US$34.0 billion in 2020, 2025, and 2030, accounting for 0.102%, 0.138%, and 0.192% of China's GDP, respectively. However, if China achieves the goals of Healthy China 2030 or the United Nations' Sustainable Development Goals for non-communicable diseases, the burden in 2030 would be < CNY144.4/US$20.9 billion. CONCLUSIONS: The population-level economic burden of liver cancer in China is currently substantial and will consistently increase in the future. Sustainable efforts in primary and secondary interventions for liver cancer need to be further strengthened. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12962-022-00370-3. BioMed Central 2022-07-23 /pmc/articles/PMC9308023/ /pubmed/35870941 http://dx.doi.org/10.1186/s12962-022-00370-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Cao, Meng-Di Liu, Cheng-Cheng Wang, Hong Lei, Lin Cao, Maomao Wang, Yuting Li, He Yan, Xin-Xin Li, Yan-Jie Wang, Xin Peng, Ji Qu, Chunfeng Feletto, Eleonora Shi, Ju-Fang Chen, Wanqing The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective |
title | The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective |
title_full | The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective |
title_fullStr | The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective |
title_full_unstemmed | The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective |
title_short | The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective |
title_sort | population-level economic burden of liver cancer in china, 2019–2030: prevalence-based estimations from a societal perspective |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308023/ https://www.ncbi.nlm.nih.gov/pubmed/35870941 http://dx.doi.org/10.1186/s12962-022-00370-3 |
work_keys_str_mv | AT caomengdi thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT liuchengcheng thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT wanghong thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT leilin thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT caomaomao thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT wangyuting thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT lihe thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT yanxinxin thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT liyanjie thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT wangxin thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT pengji thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT quchunfeng thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT felettoeleonora thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT shijufang thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT chenwanqing thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT caomengdi populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT liuchengcheng populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT wanghong populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT leilin populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT caomaomao populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT wangyuting populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT lihe populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT yanxinxin populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT liyanjie populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT wangxin populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT pengji populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT quchunfeng populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT felettoeleonora populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT shijufang populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective AT chenwanqing populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective |